Researchers are developing and testing a topical microbicide gel for drug delivery. The innovative formulation will be a combination therapy against human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV-2) infections in women.
SRI Biosciences is developing a long-lasting, two-part microbicide gel to protect women from HIV and HSV infections—and the delivery system puts the technology in the hands of women themselves.
In this podcast, Gita Shankar, director of formulations R&D, in SRI's Biosciences Division, explains how drugs taken by mouth offer many advantages to patients.
